CoChat

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

Open access
Wang, Bin, Zhao, Qin, Zhang, Yuyu, Liu, Zijing, Zheng, Zhuangzhuang, Liu, Shiyu, Meng, Lingbin, Xin, Ying, Jiang, Xin · 2021 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Abstract

With the success of immune checkpoint inhibitors (ICIs), significant progress has been made in the field of cancer immunotherapy. Despite the long-lasting outcomes in responders, the majority of patients with cancer still do not benefit from this revolutionary therapy. Increasing evidence suggests that one of the major barriers limiting the efficacy of immunotherapy seems to coalesce with the hypoxic tumor microenvironment (TME), which is an intrinsic property of all solid tumors. In addition to its impact on shaping tumor invasion and metastasis, the hypoxic TME plays an essential role in inducing immune suppression and resistance though fostering diverse changes in stromal cell biology. Therefore, targeting hypoxia may provide a means to enhance the efficacy of immunotherapy. In this review, the potential impact of hypoxia within the TME, in terms of key immune cell populations, and the contribution to immune suppression are discussed. In addition, we outline how hypoxia can be manipulated to tailor the immune response and provide a promising combinational therapeutic strategy to improve immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-020-01820-7

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Regulation of HIFs in hypoxic TME. In oxygenated conditions, HIF is hydroxylated on proline residues by PHDs, and then binds to pVHL, catalyzing its ubiquitination-dependent proteasomal degradation. In hypoxic conditions, PHDs inhibition allows HIF-α stabilization and translocation to the nucleus, where it heterodimerizes with HIF-1β. Then the HIF-1α/1β dimer binds to the transcriptional coactivator p300/CBP and HREs, activating transcription of various HIF target genes involved in angiogenesis, EMT, CSCs, metabolic reprogramming, tumor cell survival/proliferation, invasion/metastasis, and immune regulation
Fig. 1 Regulation of HIFs in hypoxic TME. In oxygenated conditions, HIF is hydroxylated on proline residues by PHDs, and then binds to pVHL, catalyzing its ubiquitination-dependent proteasomal degradation. In hypoxic conditions, PHDs inhibition allows HIF-α stabilization and translocation to the nucleus, where it heterodimerizes with HIF-1β. Then the HIF-1α/1β dimer binds to the transcriptional coactivator p300/CBP and HREs, activating transcription of various HIF target genes involved in angiogenesis, EMT, CSCs, metabolic reprogramming, tumor cell survival/proliferation, invasion/metastasis, and immune regulationCC BY · PubMed Central
Fig. 2 Graphical summary that explains the effects of hypoxia on key immune cellular populations in the TME. Hypoxia can influence the diverse aspects of tumor immunity. In general, Hypoxia can induce immune tolerance and immune escape by interfering with survival, migration and fuctions of effector cells, including effector T cell, NK-T cells, and NK cells, supporting immunosuppressive cells (Tregs, MDSCs, TAMs), and causing an increase in the production of immunosuppressive cytokines and a decrease in the release of effector cytokines
Fig. 2 Graphical summary that explains the effects of hypoxia on key immune cellular populations in the TME. Hypoxia can influence the diverse aspects of tumor immunity. In general, Hypoxia can induce immune tolerance and immune escape by interfering with survival, migration and fuctions of effector cells, including effector T cell, NK-T cells, and NK cells, supporting immunosuppressive cells (Tregs, MDSCs, TAMs), and causing an increase in the production of immunosuppressive cytokines and a decrease in the release of effector cytokinesCC BY · PubMed Central
Fig. 3 The regulation of hypoxia on immune checkpoints in the TME. a Under hypoxia, the stabilization of HIF-1α upregulates the expression of PD-L1 in hypoxic tumor cells DCs, macrophages, and MDSCs. b HIF-1α is involved in the upregulation of CD47 on tumor cell surface. The binding of CD47 to SIRPα, abundantly expressed on myeloid-linage hematopoietic cells like MDSCs and TAMs, delivers a potent “don’t eat me signal” to block phagocytosis of cancer cells. c Hypoxia upregulates the expression of HLA-G on the surface of tumor cells. The upregulated HLA-G binds to its inhibitory receptors on immune cells, inducing immune suppression and promoting immune escape by interfering with DC antigen presentation, suppressor T-cell induction, and cytotoxic attack inhibition. d Hypoxia can upregulate the expression of VISTA on myeloid cells, including MDSCs, macrophages, and DCs by the binding of HIF-1α to the HRE in VISTA promoter, suppressing T cell proliferation and activity. e Through HIF-1α stabilization, hypoxia upregulates the expression of inhibitory immune checkpoints (LAG-3 and CTLA4) and the co-stimulatory factors (CD137and OX40) on the surface of T cells, and decreased co-stimulatory molecules like CD40, CD80, and CD86 expressed on the surface of DCs
Fig. 3 The regulation of hypoxia on immune checkpoints in the TME. a Under hypoxia, the stabilization of HIF-1α upregulates the expression of PD-L1 in hypoxic tumor cells DCs, macrophages, and MDSCs. b HIF-1α is involved in the upregulation of CD47 on tumor cell surface. The binding of CD47 to SIRPα, abundantly expressed on myeloid-linage hematopoietic cells like MDSCs and TAMs, delivers a potent “don’t eat me signal” to block phagocytosis of cancer cells. c Hypoxia upregulates the expression of HLA-G on the surface of tumor cells. The upregulated HLA-G binds to its inhibitory receptors on immune cells, inducing immune suppression and promoting immune escape by interfering with DC antigen presentation, suppressor T-cell induction, and cytotoxic attack inhibition. d Hypoxia can upregulate the expression of VISTA on myeloid cells, including MDSCs, macrophages, and DCs by the binding of HIF-1α to the HRE in VISTA promoter, suppressing T cell proliferation and activity. e Through HIF-1α stabilization, hypoxia upregulates the expression of inhibitory immune checkpoints (LAG-3 and CTLA4) and the co-stimulatory factors (CD137and OX40) on the surface of T cells, and decreased co-stimulatory molecules like CD40, CD80, and CD86 expressed on the surface of DCsCC BY · PubMed Central
Fig. 4 Hypoxia-impaired susceptibility of tumor cells to effector-mediated killing. Under hypoxia conditions, tumor cells stabilize HIF-1α and activate pSTAT3, which renders them resistant to CTL-mediated lysis. Hypoxia-induced autophagy is responsible for the acquisition of resistance to CTL-mediated killing by inhibiting the degradation of pSTAT3. Similarly, in hypoxic tumor cells, excessive autophagy causes fusion of autophagosome with gigantosome to form amphisome. Subsequently, fusion of amphisome with lysosome triggers selective degradation of granzyme B, making hypoxic tumor cells resistant to NK cell-mediated killing
Fig. 4 Hypoxia-impaired susceptibility of tumor cells to effector-mediated killing. Under hypoxia conditions, tumor cells stabilize HIF-1α and activate pSTAT3, which renders them resistant to CTL-mediated lysis. Hypoxia-induced autophagy is responsible for the acquisition of resistance to CTL-mediated killing by inhibiting the degradation of pSTAT3. Similarly, in hypoxic tumor cells, excessive autophagy causes fusion of autophagosome with gigantosome to form amphisome. Subsequently, fusion of amphisome with lysosome triggers selective degradation of granzyme B, making hypoxic tumor cells resistant to NK cell-mediated killingCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Cited by

See all 350

Metadata

Authors
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X.
Affiliations
  • Jilin University (CN)
  • Moffitt Cancer Center (US)
Corresponding author
  • Xin, Ying
  • Jiang, Xin
Venue
Journal of Experimental & Clinical Cancer Research
Published
2021-01-09
Volume
40
Issue
1
Pages
24-24
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W3118395892
Cited by
315
References
111
Citations by year
2026: 36 · 2025: 51 · 2024: 70 · 2023: 54 · 2022: 71 · 2021: 33
FWCI
7.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the National Natural Science Foundation of China (81570344)
  • National Key R&D Program of China (2017YFC0112100)
  • the Education Department Foundation of Jilin Province (JJKH20201036KJ)
  • the Health and Family Planning Commission of Jilin Province Foundations (2016Q034 and 2017J11)
  • the Norman Bethune Program of Jilin University (2015225 and 2015203)
  • Jilin Scientific and Technological Development Program (20180414039GH and 20190201200JC)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
tumor hypoxia, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, immunosuppression, immune evasion, stromal cells, immune cell subsets, combination therapy, tumor invasion and metastasis
MeSH terms
Humans, Immunotherapy, Neoplasms, Cell Hypoxia, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s13046-020-01820-7
The paper
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021). Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-020-01820-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.